Suzhou AstraBio Technology Co. Ltd has completed tens of millions of yuan of Pre-B round of financing, will be the core of the neurological markers, to further improve the neurological blood markers screening and diagnostic solutions.
2024-02
AD blood reagents kit based on single-molecule analysis strategy successfully receives NMPA approved:
β Amyloid 1-42 reagents kit
Phosphorylated tau 181 reagents kit
2023-08
ASTRABIO passed the ISO 13485:2016 medical device quality management system certification.
2022-11
The fully automated single-molecule immunoassay analyzer AST-DxSMD developed by ASTRABIO has now under registration for application as an innovative medical device.
2022-06
ASTRABIO completed nearly 100 million CNY Series A financing to create a closed-loop industrial chain for clinical transformation of novel biomarkers.
2022-06
Our first fully automated fluorescence immunoassay analyzer based on single-molecule analysis strategy approved as Class II medical device.